CA3060266A1 - Prevention and reversal of inflammation induced dna damage - Google Patents

Prevention and reversal of inflammation induced dna damage Download PDF

Info

Publication number
CA3060266A1
CA3060266A1 CA3060266A CA3060266A CA3060266A1 CA 3060266 A1 CA3060266 A1 CA 3060266A1 CA 3060266 A CA3060266 A CA 3060266A CA 3060266 A CA3060266 A CA 3060266A CA 3060266 A1 CA3060266 A1 CA 3060266A1
Authority
CA
Canada
Prior art keywords
ape1
pharmaceutically acceptable
subject
apx3330
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3060266A
Other languages
English (en)
French (fr)
Inventor
Mark R. Kelley
Jill Fehrenbacher
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of CA3060266A1 publication Critical patent/CA3060266A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3060266A 2017-04-17 2018-04-16 Prevention and reversal of inflammation induced dna damage Pending CA3060266A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762486033P 2017-04-17 2017-04-17
US62/486,033 2017-04-17
PCT/US2018/027786 WO2018194976A1 (en) 2017-04-17 2018-04-16 Prevention and reversal of inflammation induced dna damage

Publications (1)

Publication Number Publication Date
CA3060266A1 true CA3060266A1 (en) 2018-10-25

Family

ID=63856081

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3060266A Pending CA3060266A1 (en) 2017-04-17 2018-04-16 Prevention and reversal of inflammation induced dna damage

Country Status (5)

Country Link
US (2) US20190117602A1 (https=)
EP (1) EP3440047A4 (https=)
JP (1) JP2020516663A (https=)
CA (1) CA3060266A1 (https=)
WO (1) WO2018194976A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190160034A1 (en) * 2017-03-20 2019-05-30 Indiana University Research And Technology Corporation Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
JP7266304B2 (ja) 2017-04-21 2023-04-28 ユニヴァーシティー オブ タスマニア 治療化合物および方法
EP3897601A4 (en) * 2018-12-17 2022-08-31 Indiana University Research And Technology Corporation TREATMENT OF GASTROINTESTINAL DISEASES AND THEIR SYMPTOMS
EP4587003A2 (en) 2022-09-14 2025-07-23 Opus Genetics, Inc. Salts and esters of apx3330 and therapeutic uses thereof
CN119097711A (zh) * 2024-09-11 2024-12-10 山东大学齐鲁医院 Ape1抑制剂在制备治疗鼻窦炎药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801949A1 (en) * 1996-04-15 1997-10-22 Eisai Co., Ltd. Hypoglycemic quinone derivative
JPH1067653A (ja) * 1996-06-17 1998-03-10 Eisai Co Ltd 関節疾患治療剤
EP0813866A3 (en) * 1996-06-17 1999-01-20 Eisai Co., Ltd. Therapeutic agent for joint diseases
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
AU2008304619C1 (en) * 2007-09-26 2020-06-04 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
KR20110103442A (ko) 2008-12-23 2011-09-20 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 염증 표적화 입자
GB201020397D0 (en) 2010-12-02 2011-01-12 Univ Nottingham Compounds
WO2012148889A1 (en) 2011-04-28 2012-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of human apurinic/apyrimidinic endonuclease 1
KR101982669B1 (ko) * 2011-05-26 2019-05-27 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ape1 매개된 질환을 치료하기 위한 퀴논 화합물
US20140128398A1 (en) * 2011-06-03 2014-05-08 Indiana University Research And Technology Corporation Compounds, compositions and methods for treating oxidative dna damage disorders
CN107184572B (zh) 2017-03-09 2020-07-28 中山大学 一种ape1抑制剂及其在制备用于治疗肿瘤和血管异常增生性疾病药物中的应用

Also Published As

Publication number Publication date
US20200253904A1 (en) 2020-08-13
JP2020516663A (ja) 2020-06-11
WO2018194976A1 (en) 2018-10-25
US11351130B2 (en) 2022-06-07
EP3440047A4 (en) 2020-04-01
EP3440047A1 (en) 2019-02-13
US20190117602A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
US11351130B2 (en) Prevention and reversal of inflammation induced DNA damage
Kelley et al. Identification and characterization of new chemical entities targeting apurinic/apyrimidinic endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathy
McConoughey et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease
Ding et al. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma
Oppermann et al. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling
US9597369B2 (en) Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers
US20150025017A1 (en) Compositions and methods for treating cancer
Ge et al. Phosphodiesterase 4D acts downstream of Neuropilin to control Hedgehog signal transduction and the growth of medulloblastoma
Lee et al. Tissue transglutaminase activates cancer-associated fibroblasts and contributes to gemcitabine resistance in pancreatic cancer
Zou et al. TRPC5-induced autophagy promotes the TMZ-resistance of glioma cells via the CAMMKβ/AMPKα/mTOR pathway
Li et al. RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance
Cai et al. Upregulation of nuclear factor of activated T-cells by nerve injury contributes to development of neuropathic pain
Fan et al. Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo
Wu et al. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis
Garcia et al. Acss2/HIF-2 signaling facilitates colon cancer growth and metastasis
Zhao et al. Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma
Duan et al. Blocking Mammalian Target of Rapamycin (mTOR) Alleviates Neuropathic Pain Induced by Chemotherapeutic Bortezomib.
Traver et al. Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC
Condurat et al. Verteporfin-induced proteotoxicity impairs cell homeostasis and survival in neuroblastoma subtypes independent of YAP/TAZ expression
Zhu et al. Calcyphosine promotes the proliferation of glioma cells and serves as a potential therapeutic target
Jones et al. CPEB1 regulates β‐catenin mRNA translation and cell migration in astrocytes
Yang et al. HIF-1α/MMP-9 promotes spinal cord central sensitization in rats with bone cancer pain
Li et al. EHMT2 promotes tumorigenesis in GNAQ/11-mutant uveal melanoma via ARHGAP29-mediated RhoA pathway
Chen et al. Proteolytic fragments of laminin promote excitotoxic neurodegeneration by up-regulation of the KA1 subunit of the kainate receptor
Burton et al. Imipridones and dopamine receptor antagonism in the therapeutic management of gliomas

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230323

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240913

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250116

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250513

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250513